Myriad Genetics Share Price Today
(NASDAQ: MYGN)

Name: Myriad Genetics Share Price Today (NASDAQ: MYGN) - Myriad Genetics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Myriad Genetics share price is $14.18 & ₹1,229.77 as on 22 Feb 2025, 2.30 'hrs' IST

$14.18

▲

-0.8

(-5.34%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Myriad Genetics share price in Dollar and Rupees. Guide to invest in Myriad Genetics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Myriad Genetics, along with analyst recommendations, forecasts, and comprehensive financials.

Myriad Genetics share price movements

Today's Low: $14.14
Today's High: $15.18
$14.18
0.28%
Downside
Day's Volatility :6.85%
Upside
6.59%
52 Weeks Low: $12.04
52 Weeks High: $29.30
$14.18
15.09%
Downside
52 Weeks Volatility :58.91%
Upside
51.6%

Myriad Genetics (MYGN) Returns

Period	Myriad Genetics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-9.74%	1.6%	0.0%
6 Months	-48.72%	-5.8%	0.0%
1 Year	-38.16%	-1.0%	0.0%
3 Years	-42.57%	15.7%	-9.0%

Myriad Genetics (MYGN) Key Statistics

in dollars & INR

Previous Close	$14.98
Open	$15.13
Today's High	$15.18
Today's Low	$14.14
Market Capitalization	$1.4B
Today's Volume	$868.2K
52 Week High	$29.3
52 Week Low	$12.04
Revenue TTM	$823.6M
EBITDA	$-33.9M
Earnings Per Share (EPS)	$-1.28
Profit Margin	-14.09%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-16.4%

How to invest in Myriad Genetics Stock (MYGN) from India?

It is very easy for Indian residents to invest directly in Myriad Genetics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Myriad Genetics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Myriad Genetics or MYGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Myriad Genetics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Myriad Genetics shares which would translate to 0.061 fractional shares of Myriad Genetics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Myriad Genetics, in just a few clicks!

Returns in Myriad Genetics (MYGN) for Indian investors in Rupees

The Myriad Genetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Myriad Genetics investment value today

Current value as on today

₹66,490

Returns

₹33,510

(-33.51%)

Returns from Myriad Genetics Stock

₹38,160 (-38.16%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Myriad Genetics (MYGN)

-50%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Myriad Genetics Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Myriad Genetics

BlackRock Inc
16.96%
Vanguard Group Inc
11.63%
Wellington Management Company LLP
6.60%
Millennium Management LLC
5.69%
State Street Corp
5.17%
Earnest Partners LLC
4.35%

Analyst Recommendation on Myriad Genetics

Buy

50%Buy

33%Hold

16%Sell

Based on 18 Wall street analysts offering stock ratings for Myriad Genetics(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Myriad Genetics Stock (MYGN)

What analysts predicted

Upside of 41.71%

Target:

$20.09

Current:

$14.18

Insights on Myriad Genetics Stock (Ticker Symbol: MYGN)

Price Movement
In the last 1 month, MYGN stock has moved up by 11.1%
Increasing Revenue
Revenue is up for the last 9 quarters, 156.4M → 213.3M (in $), with an average increase of 3.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -36.7M → -22.1M (in $), with an average increase of 66.1% per quarter
MYGN vs A (1 yr)
In the last 1 year, Agilent Technologies Inc. has given 2.5% return, outperforming this stock by 40.1%
MYGN vs A (3 yr)
In the last 3 years, Agilent Technologies Inc. has given 7.4% return, outperforming this stock by 47.8%
Price to Sales
ForMYGN every $1 of sales, investors are willing to pay $1.5, whereas for Agilent Technologies Inc., the investors are paying $6.0 for every $1 of sales.

MYGN Myriad Genetics Financials in INR & Dollars

	FY21	Y/Y Change
Revenue	$690.6M	↑ 23.99%
Net Income	$-27.2M	↓ 87.84%
Net Profit Margin	-3.94%	↑ 36.22%

	FY21	Y/Y Change
Revenue	$690.6M	↑ 23.99%
Net Income	$-27.2M	↓ 87.84%
Net Profit Margin	-3.94%	↑ 36.22%

	FY22	Y/Y Change
Revenue	$678.4M	↓ 1.77%
Net Income	$-112.0M	↑ 311.76%
Net Profit Margin	-16.51%	↓ 12.57%

	FY22	Y/Y Change
Revenue	$678.4M	↓ 1.77%
Net Income	$-112.0M	↑ 311.76%
Net Profit Margin	-16.51%	↓ 12.57%

	FY23	Y/Y Change
Revenue	$753.2M	↑ 11.03%
Net Income	$-263.3M	↑ 135.09%
Net Profit Margin	-34.96%	↓ 18.45%

	FY23	Y/Y Change
Revenue	$753.2M	↑ 11.03%
Net Income	$-263.3M	↑ 135.09%
Net Profit Margin	-34.96%	↓ 18.45%

	Q2 FY23	Q/Q Change
Revenue	$183.5M	↑ 1.27%
Net Income	$-116.1M	↑ 112.25%
Net Profit Margin	-63.27%	↓ 33.08%

	Q3 FY23	Q/Q Change
Revenue	$191.9M	↑ 4.58%
Net Income	$-61.3M	↓ 47.2%
Net Profit Margin	-31.94%	↑ 31.33%

	Q4 FY23	Q/Q Change
Revenue	$196.6M	↑ 2.45%
Net Income	$-31.2M	↓ 49.1%
Net Profit Margin	-15.87%	↑ 16.07%

	Q1 FY24	Q/Q Change
Revenue	$202.2M	↑ 2.85%
Net Income	$-26.0M	↓ 16.67%
Net Profit Margin	-12.86%	↑ 3.01%

	Q2 FY24	Q/Q Change
Revenue	$211.5M	↑ 4.6%
Net Income	$-36.7M	↑ 41.15%
Net Profit Margin	-17.35%	↓ 4.49%

	Q3 FY24	Q/Q Change
Revenue	$213.3M	↑ 0.85%
Net Income	$-22.1M	↓ 39.78%
Net Profit Margin	-10.36%	↑ 6.99%

	FY21	Y/Y Change
Profit	$493.0M	-

	FY22	Y/Y Change
Profit	$476.4M	-

	FY23	Y/Y Change
Profit	$517.0M	-

	Q2 FY23	Q/Q Change
Profit	$125.7M	↑ 3.03%

	Q3 FY23	Q/Q Change
Profit	$134.3M	↑ 6.84%

	Q4 FY23	Q/Q Change
Profit	$135.0M	↑ 0.52%

	Q1 FY24	Q/Q Change
Profit	$137.6M	↑ 1.93%

	Q2 FY24	Q/Q Change
Profit	$147.1M	↑ 6.9%

	Q3 FY24	Q/Q Change
Profit	$149.8M	↑ 1.84%

	FY21	Y/Y Change
Operating Cash Flow	$-26.9M	↓ 132.14%
Investing Cash Flow	$56.0M	-
Financing Cash Flow	$-1000.0K	↓ 100.55%

	FY22	Y/Y Change
Operating Cash Flow	$18.2M	↑ 0.0%
Investing Cash Flow	$274.4M	-
Financing Cash Flow	$-150.6M	↑ 0.0%

	FY23	Y/Y Change
Operating Cash Flow	$-106.3M	↑ 0.0%
Investing Cash Flow	$-77.5M	-
Financing Cash Flow	$-8.0M	↑ 0.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-900.0K	↓ 97.29%
Investing Cash Flow	$11.8M	↓ 65.9%
Financing Cash Flow	$38.4M	↓ 883.67%

Myriad Genetics Technicals Summary

Sell

Neutral

Buy

Myriad Genetics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Myriad Genetics (MYGN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Myriad Genetics Inc.	10.61%	-48.72%	-38.16%	-42.57%	-20.91%
Agilent Technologies Inc.	-10.33%	-3.64%	2.95%	1.23%	73.31%
Idexx Laboratories, Inc.	5.91%	-6.47%	-20.55%	-13.34%	74.51%
Thermo Fisher Scientific, Inc.	-8.75%	-12.06%	-5.49%	-3.14%	72.26%
Danaher Corp.	-16.11%	-21.58%	-16.46%	-24.72%	38.14%
Iqvia Holdings Inc.	-7.71%	-22.92%	-22.81%	-18.36%	27.88%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Myriad Genetics Inc.	NA	NA	1.4	0.13	-0.16	-0.05	NA	8.04
Agilent Technologies Inc.	30.56	30.56	2.31	5.57	0.22	0.09	0.01	20.68
Idexx Laboratories, Inc.	42.36	42.36	4.5	11.97	0.58	0.22	NA	19.49
Thermo Fisher Scientific, Inc.	32.58	32.58	2.05	23.33	0.13	0.05	0.0	129.72
Danaher Corp.	39.31	39.31	3.85	7.65	0.08	0.04	0.01	68.9
Iqvia Holdings Inc.	25.51	25.51	1.04	11.9	0.23	0.05	NA	34.45

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Myriad Genetics Inc.	Buy	$1.4B	-20.91%	NA	-14.09%
Agilent Technologies Inc.	Buy	$38.6B	73.31%	30.56	19.8%
Idexx Laboratories, Inc.	Buy	$37.1B	74.51%	42.36	22.78%
Thermo Fisher Scientific, Inc.	Buy	$205.7B	72.26%	32.58	14.77%
Danaher Corp.	Buy	$149.5B	38.14%	39.31	16.33%
Iqvia Holdings Inc.	Buy	$33.6B	27.88%	25.51	8.91%

Myriad Genetics Dividend announcements

Myriad Genetics Earnings
Myriad Genetics’s price-to-earnings ratio stands at None
Read More

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Organization	Myriad Genetics
Employees	2700
CEO	Mr. Paul J. Diaz J.D.
Industry	Health Technology

Management People of Myriad Genetics

Name	Title
Mr. Paul J. Diaz J.D.	CEO, President & Director
Mr. Samraat S. Raha	Chief Operating Officer
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer
Mr. Mark S. Verratti	Chief Commercial Officer
Mr. Scott J. Leffler	Chief Financial Officer
Ms. Natalie Munk	Senior VP & Chief Accounting Officer
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer
Mr. Matthew Scalo	Senior Vice President of Investor Relations
Ms. Jennifer L. Fox	Chief Legal Officer
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer

Important FAQs about investing in MYGN Stock from India :

What is Myriad Genetics share price today?

Myriad Genetics share price today stands at $14.18, Open: $15.13 ; Previous Close: $14.98 ; High: $15.18 ; Low: $14.14 ; 52 Week High: $29.30 ; 52 Week Low: $12.04.

The stock opens at $15.13, after a previous close of $14.98. The stock reached a daily high of $15.18 and a low of $14.14, with a 52-week high of $29.30 and a 52-week low of $12.04.

Can Indians buy Myriad Genetics shares?

Yes, Indians can invest in the Myriad Genetics (MYGN) from India.

With INDmoney, you can buy Myriad Genetics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Myriad Genetics at zero transaction cost.

How can I buy Myriad Genetics shares from India?

It is very easy to buy Myriad Genetics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Myriad Genetics (MYGN) be purchased?

Yes, you can buy fractional shares of Myriad Genetics with INDmoney app.

What are the documents required to start investing in Myriad Genetics stocks?

To start investing in Myriad Genetics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.